TransMedics Group, Inc. (NASDAQ:TMDX) Stock Has Average Price Target of $115.60 According to Brokerages

Key Points

• Analysts maintain a “Hold” consensus on TransMedics Group, with six hold, five buy and one sell rating. The average 12-month price target is $115.60, although recent target changes included UBS lowering its target to $77 and TD Cowen assigning a $120 target.
• TransMedics shares opened at $67.12, well below their 12-month high of $156.00 and the 50-day and 200-day moving averages of $82.15 and $95.26, respectively.
• The company’s latest quarterly revenue rose 20.7% year over year to $189.95 million, exceeding estimates, but adjusted earnings of $0.44 per share missed the $0.50 consensus. Director David Weill also purchased 1,336 shares, while institutional investors own 99.67% of the stock.

Shares of TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) have earned an average rating of "Hold" from the twelve research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $115.60.

Several analysts have weighed in on the company. UBS Group lowered their price target on TransMedics Group from $80.00 to $77.00 and set a "neutral" rating on the stock in a report on Wednesday, August 5th. Zacks Research lowered TransMedics Group from a "hold" rating to a "strong sell" rating in a research report on Monday, July 6th. Needham & Company LLC reaffirmed a "buy" rating on shares of TransMedics Group in a research note on Friday, September 11th. TD Cowen reaffirmed a "buy" rating and set a $120.00 target price on shares of TransMedics Group in a report on Tuesday, September 8th. Finally, Weiss Ratings upgraded shares of TransMedics Group from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday, August 31st.

Insider Activity

In other news, Director David Weill acquired 1,336 shares of the stock in a transaction dated Friday, September 11th. The stock was purchased at an average cost of $81.63 per share, with a total value of $109,057.68. Following the completion of the purchase, the director owned 16,392 shares in the company, valued at approximately $1,338,078.96. The trade was a 8.87% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 6.90% of the company's stock.

Institutional Trading of TransMedics Group

Several large investors have recently added to or reduced their stakes in TMDX. Trek Financial LLC bought a new stake in TransMedics Group in the third quarter worth $11,989,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of TransMedics Group by 700.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 800 shares of the company's stock valued at $67,000 after acquiring an additional 700 shares in the last quarter. D.A. Davidson & CO. increased its holdings in shares of TransMedics Group by 1.4% during the third quarter. D.A. Davidson & CO. now owns 16,060 shares of the company's stock valued at $1,340,000 after acquiring an additional 228 shares in the last quarter. Redmond Asset Management LLC bought a new position in TransMedics Group in the 3rd quarter worth about $237,000. Finally, Pinnacle Wealth Planning Services Inc. boosted its stake in TransMedics Group by 24.9% in the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 874 shares of the company's stock worth $73,000 after purchasing an additional 174 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $67.12 on Friday. The firm has a market capitalization of $2.32 billion, a PE ratio of 17.25, a P/E/G ratio of 0.92 and a beta of 1.94. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. The company has a 50-day moving average price of $82.15 and a two-hundred day moving average price of $95.26. TransMedics Group has a twelve month low of $60.10 and a twelve month high of $156.00.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.06). The business had revenue of $189.95 million during the quarter, compared to the consensus estimate of $184.00 million. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The business's revenue for the quarter was up 20.7% on a year-over-year basis. During the same period last year, the firm earned $0.92 EPS. Equities analysts forecast that TransMedics Group will post 1.46 EPS for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company's primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.